Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THE_#_OF_SHARES_OUTSTANDING_HASNT_CHANGED_SINCE_OCTOBER_SEE_LINK_BELOW!_Outstanding Shares_56,838,924_a/o Nov 01, 2016
http://www.otcmarkets.com/stock/CVSI/profile
Share Statistics
Avg Vol (3 month) 3 1.08M
Avg Vol (10 day) 3 2.34M
Shares Outstanding 5 56.84M
Float 41.08M
https://finance.yahoo.com/quote/CVSI/key-statistics?p=CVSI
It's_a_HEADFAKE!_The_Minute_You_Slap_The_Ask_All_The_Sell_Orders_Instantly_Vanish! There using the 100k to trick people into selling!
$CVS¡-$MJNA's-Partner-Next-One-To-Run!-Long-Both-Cheers! Here's comes the next surge!
$CVSI-Only-24-Million-MARKET-CAP-2X-Revenues, in my opinion is one of the cheapest Marijuana based companies. The company was formerly known as $CANV #Cannavest
This company is one of the only Marijuana stocks to have sales in excess of $10 million. In 2014 The stock ran from under $1 to over $200.00 per share! With any volume this stock will soar to over $1.00 like $AMMJ and $CNAB
BLUE-SKY'S-LEVEL-2-CLEAR-ALL-THE-WAY-TO-.90's-WITH-VERY-FEW-SELL-ORDERS-IN-BETWEEN! WE are Free To Run Right Now with Any Volume!
CVSI WILL BE HUGE! RT $CVSI has 3K acres, has research land in Kentucky for studies. They're looking to kick start the #HEMP Revolution
100,000+BLOCK-BUYERS-ARE-COMING-LAST-CHANCE-TO-BUY-AT-THIS-LEVEL
200K-BUY-AT-THE-ASK-WOULD-RUN-THIS-TO-.60+CENTS-IN-5-MINUTES! Easy Money buying here!
HUGE CVSI-BID-ASK-SPREAD-Means-Shares-Are-Getting-Scarce-CLEAR-BUY-SIGNAL
CVSI Headed Over $1.00=»$2.00+ Short Term! The same manipulators that drove this down, will drive it back up and most of the posters on this board will miss the run! ;)
IT'S Manipulation! Don't fall for the BS! We all know that this is the most undervalued Marijuana based company publicly trading! People will soon realize the value here is well above its current market cap of $24 million! Buying more here!
I'm showing its moving Up. About to Gap Above .50 Cents. There was a false trade around 8am that skewed the quote! It was a false trade.
All The Marijuana Stocks Gapping Up Now after some bizarre trade activity on many of them around 8AM
RT $CVSI-AKA-$CANV-Investing-in-Marijuana-and-Hemp-Stocks
The Market Gets Bigger Following Election
| MENAFN.COM http://menafn.com/1095047691/Investing-in-Marijuana-and-Hemp-Stocks-The-Market-Gets-Bigger-Following-Election?src=RSS
That's correct! Thanks for saving me time, and responding!
IT'S NOW OFFICIAL! Gay billionaire Peter Thiel joins Donald Trump’s transition team / LGBTQ Nation
http://www.lgbtqnation.com/2016/11/gay-billionaire-peter-thiel-joins-donald-trumps-transition-team/
Paypal founder Peter Thiel becomes marijuana's first big investor | Business | The Guardian https://www.theguardian.com/business/2015/jan/08/cannabis-investor-peter-theil-paypal-founder
Outstanding Shares 56,838,924 a/o Nov01,2016 Float:37.61M
These figures are Accurate!
OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com http://www.otcmarkets.com/stock/CVSI/profile
CVSI Key Statistics | CV SCIENCES INC COM Stock - Yahoo! Finance http://finance.yahoo.com/q/ks?s=CVSI+Key+Statistics
CT Order =Confidential Treatment Order! It's a filing that is submitted to the SEC, but kept private for Competitive Reasons. They are legally obligated to file anything that's considered "Material".
They do not want trade secrets and or business deals to be exposed, to the public until they have certain measures put in place, which could be patent issuance or a merger acquisition, breakthrough Drug , New Product or buyout agreement.
There's something going on, that they are going to make public, Soon! :)
RT $CVSI AKA $CANV CV Sciences Letter 2 Shareholders #CNBC #Marijuana #Hemp #CBD #Stocks #Cannavest #Weed #Pot #CanX
CV Sciences, Inc. Issues Letter to Shareholders
LAS VEGAS, NV--(Marketwired - September 27, 2016) - CV Sciences, Inc. (OTCBB: CVSI) (the "Company", "CV Sciences", "our" or "we"), issued a letter today to its shareholders discussing recent events and highlights.
Highlights of the letter include discussion of the following recent accomplishments:
Acquisition of CanX Inc. and focus on the development and commercialization of innovative medicines.
Multi-billion market opportunity presented by initial drug candidate (CVSI-007), a proprietary chewing gum that combines synthetic CBD and nicotine to effectively treat smokeless tobacco addiction.
Review of drug development program and timeline of achievements and upcoming milestones.
Update of the Company's CBD Consumer Division, which has grown from 120 retail locations to now over 700 locations.
Macro factors that continue to drive the market for natural CBD and hemp products.
Review of corporate priorities in the Company's pharmaceutical and consumer product divisions and how to effectively maximize the value of its operating assets for the benefit of shareholders.
To read the Letter to Shareholders in full, please visit: http://cvsciences.com/wp-content/uploads/2016/09/CV-Sciences-CEO-Letter.Sep14.2016.pdf
About CV Sciences, Inc.
CV Sciences, Inc. (OTCBB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
http://www.otcmarkets.com/stock/CVSI/news/CV-Sciences--Inc--Issues-Letter-to-Shareholders?id=141363&b=y
$CVSI AKA $CANV Cannavest-SUED-THE-DEA-AND-WON! $CVSI AKA $CANV Cannavest Vice President Chris Boucher Talks Hemp CBD
#HEMP #Weed #CBD #Cannabis #Weed #Potstocks
RT $CVSI AKA $CANV #Cannavest CBD Supply Side West Sanjay Gupta - #HEMP
$CVSI AKA $CANV CV Sciences AKA #Cannavest Plus CBD Oil by CV Sciences Review - YouTube
Major News Coming! Confidential Treatment Order (ct Order)
They have something major in the hopper!
http://ih.advfn.com/p.php?pid=nmona&article=72244881
That's Because $CVSI is one of the only Real Marijuana based companies selling real products with a real staff, Patent and intellectual property.
The rest of the companies publicly trading don't have products, sales or even staff to answer phones.
It amazes me that we have a market cap of $24 million, only 2 X Sales while the others trade with market caps at 100 million, 300 million or 500 million +.
Soon we will fly, when people actually do due diligence and this company is on the top of their lists!
Also to add to the Options Question!! Options give the employees the rights to purchase shares at a specific price. They were issued warrants. I think we can all agree that they want the share price to explode higher, so their options increase in value! At the same time they are funding the company with additional cash if they exercise there warrants which is better than convertible debt and OK in my book!
$CVSI-A/K/A-$CANV-Market-Cap-$24,979,200___&___SHARES-SOLD-SHORT_REPORT
OTC Short Report, Short Data Stock Positions, Trading Short Interest
http://otcshortreport.com/?index=CVSI&action=view
Date Close High Low Volume Short Volume % of Vol Shorted
Nov 11 0.48 0.50 0.36 1,816,107 522,592 28.78%
Nov 10 0.43 0.55 0.40 2,641,046 823,541 31.18%
Nov 09 0.55 0.61 0.46 1,993,751 592,951 29.74%
Nov 08 0.61 0.72 0.54 3,722,158 1,343,595 36.10%
Nov 07 0.69 0.71 0.59 2,352,051 827,092 35.16%
Nov 04 0.57 0.66 0.52 3,745,963 804,853 21.49%
Nov 03 0.64 0.83 0.64 2,575,445 953,611 37.03%
Nov 02 0.83 0.89 0.74 1,588,589 589,097 37.08%
Nov 01 0.89 0.96 0.82 1,569,035 488,807 31.15%
Oct 31 0.93 0.99 0.83 1,934,323 692,951 35.82%
Oct 28 0.80 0.80 0.73 1,512,863 686,802 45.40%
Oct 27 0.70 0.87 0.64 2,589,285 825,538 31.88%
Oct 26 0.85 0.88 0.82 935,975 336,974 36.00%
Oct 25 0.83 0.94 0.81 2,053,667 582,499 28.36%
Oct 24 0.89 0.89 0.73 2,075,946 831,864 40.07%
Oct 21 0.70 0.71 0.64 1,056,301 433,270 41.02%
Oct 20 0.63 0.71 0.61 1,605,430 367,364 22.88%
Oct 19 0.69 0.81 0.68 1,507,837 394,813 26.18%
Oct 18 0.74 0.77 0.63 2,949,375 970,777 32.91%
Oct 17 0.58 0.60 0.48 1,329,275 548,939 41.30%
Oct 14 0.48 0.51 0.46 505,944 187,690 37.10%
Oct 13 0.48 0.54 0.43 1,679,700 703,090 41.86%
NOV15-NOV18 $CVSI AKA $CANV SPECIAL PRESENTATION, at the BIG MJ Expo Next Week. (Gonna Get alot more investor awareness)
(There hasn't been a press release on this yet, I just happened to of found it!)
Marijuana Business Conference Expo
November 15, 2016: Pre-Conference Workshops
November 16-18, 2016: Main Conference & Expo
The Rio All-Suites Hotel & Casino | Las Vegas, NV
Call (401) 354-7555 x1
Email CustomerService@MJBizDaily.com
CV Sciences – PlusCBDoil – Booth #506
Tango Room, 2:00-3:00 pm
The Cannabis Disruption: Bringing Hemp Back
Hemp-derived cannabidiol, or CBD, has been receiving a lot of attention for its tremendous promise on human health. Discover exactly why we believe hemp-derived CBD is here to stay, and what measures this category leader is doing to ensure the safest and most trusted CBD products available via our PlusCBD Oil™ brand.
https://mjbizconference.com/vendor-presentations/
Nov 14 - Nov 16th CVSI is PRESENTING! MJ for MDs Marijuana for Medical Professionals Conference / DENVER COLORODO
https://marijuanaformedicalprofessionals.com/
CV Sciences, Inc. Webcast on its CBD-based Drug Development Program on November 12, 2016 Recording now available:
Company Discussed Advances in Program for Development of Therapeutic Products for Cessation of Smokeless Tobacco Use and Addiction -- A Market Estimated to Exceed $2 Billion in the U.S.
CV Sciences - CBD Based Drug Development Program Presented by Joseph Dowling
Published on Nov 11, 2016
CV Sciences CFO, Joseph Dowling, discussed the Company's initial drug candidate (CVSI-007), which is a chewing gum that combines synthetic CBD and nicotine. This drug development program and specifically its drug candidate utilizes synthetically-formulated CBD for use in treatment of smokeless tobacco addiction.
MUST-READ-I-REACHED-OUT-TO-PETER-THIEL-ABOUT-CV-SCIENCES-YESTERDAY!-CVSI-A/K/A-CANV-CANNAVEST
IN MY OPINION, WE ARE GOING TO BE OVER $1.00 PER SHARE MUCH SOONER THAN SOME THINK! ITS AMAZING HOW MANY PEOPLE WERE SHAKEN OUT OF THEIR SHARES THIS WEEK DUE TO THE VOLATILITY, BUT I HOPE YOU GUYS UNDERSTAND THIS IS A GAME, WHERE THEY WILL DO WHATEVER THEY CAN TO STEAL YOUR SHARES BY SCARING THE HECK OUT OF YOU!
HUGE NEWS! Peter Thiel to join the Trump transition team... People who sold yesterday are going to be extremely angry they did!
DISCLOSURE: I PERSONALLY REACHED OUT TO PETER THIEL & I PERSONALLY KNOW ANTHONY SCARAMUCCI & HIS FAMILY AND HAVE INFORMED THEM ABOUT CV SCIENCES - DO NOT BE SHOCKED IF THEY GET INVOLVED!
Thiel, Scaramucci get spots on Trump’s transition team
http://www.marketwatch.com/story/thiel-scaramucci-get-spots-on-trumps-transition-team-2016-11-11?mod=MW_video_top_stories
How a Silicon Valley billionaire helped get marijuana fully legalized in California
http://finance.yahoo.com/news/heres-silicon-valley-billionaire-helped-170000806.html
TRUMP IS BRINGING ON BILLIONAIRE CANNABIS INVESTOR AND GETTING RID OF THAT PIG CHRISTIE! He's doing this because he knows 60% of the US Supports Cannabis and needs someone who understands how to legalize it nationally and to help develop infrastructure to support Marijuana!
Billionaire venture capitalist Peter Thiel is said to be joining President-elect Donald Trump’s transition team — and possibly leading it.
Business columnist Dan Primack reported late Thursday on LinkedIn that Thiel had agreed to join Trump’s team.
http://www.marketwatch.com/story/could-peter-thiel-lead-trumps-transition-team-2016-11-10
Paypal founder Peter Thiel becomes marijuana's first big investor
Thiel’s Founders Fund is the first institutional investor to put money into the nascent cannabis industry, which is still illegal in half the US
https://www.theguardian.com/business/2015/jan/08/cannabis-investor-peter-theil-paypal-founder
Founders Fund joins $75 million investment in cannabis company
Founders Fund, the investment firm created by Peter Thiel, has joined a $75 million funding round for Privateer Holdings. Its subsidiary, Marley Natural, sells marijuana.
http://fortune.com/2015/01/08/founders-fund-privateer-holdings/
https://www.yahoo.com/news/silicon-valley-venture-capitalist-peter-014206689.html
Peter Thiel’s Founders Fund pours funds into the company behind Leafly, an online cannabis community
http://venturebeat.com/2015/01/08/peter-thiels-founders-fund-pours-funds-into-the-company-behind-leafly-an-online-cannabis-community/
Marijuana investor Privateer raises $40 million on eve of U.S. elections
Thursday, November 03, 2016 7:41 p.m. CDT
SAN FRANCISCO (Reuters) - Marijuana private equity investor Privateer Holdings has raised $40 million in convertible debt ahead of next week's elections, with pot legalization on the ballot in nine U.S. states.
Several investors rushed to place their funds, while others held back to wait for the election results.
Of the nine states that will vote on Tuesday on legalizing medical or recreational marijuana, California ranks as the most important.
The most populous U.S. state is considering allowing recreational adult use.
If the measure passes, it is expected to legitimize part of a multi-billion-dollar black market and open new opportunities for companies ranging from software to pot delivery.
Financial services firm Cowen and Co forecasts a $50 billion U.S. market in a decade, up from $6 billion in legal sales today.
U.S. law prohibits marijuana but federal agencies so far have limited their enforcement effort for companies which follow local laws in states that have legalized pot.
Seattle-based Privateer is one of several funds and investment companies targeting marijuana businesses. It said investors were divided on when to make their moves.
“Most of the potential lead investors wanted to wait until after next Tuesday to invest,” Chief Executive Brendan Kennedy said in an interview.
Others were ready to invest, but it was difficult to agree on how to value Privateer, with the outcome of the state votes unclear. The presidential race was a secondary issue, he added.
“This is a way to sort of take capital from investors without having to negotiate the price," he said. Privateer hopes to raise $100 million in the next round, including the notes.
The valuation of the company will be set when the round closes, and convertible note holders will get a 15 percent discount when they get equity in Privateer, he said.
The company plans to put more than half of the round in companies outside the United States, including Canada and potentially Australia, he said.
(Reporting by Peter Henderson; Editing by Leslie Adler)
http://kdal610.com/news/articles/2016/nov/04/marijuana-investor-privateer-raises-40-million-on-eve-of-us-elections/
Peter Thiel donates to California pot legalization campaign | The Sacramento Bee
http://www.sacbee.com/news/politics-government/capitol-alert/article112777458.html
Donald Trump, Marijuana, Rolling Stones: Your Thursday Evening Briefing
- NYTimes.com http://mobile.nytimes.com/2016/11/10/briefing/donald-trump-marijuana-rolling-stones.html
Recording now available: CV Sciences, Inc. Webcast on its CBD-based Drug Development Program on November 12, 2016
Company Discussed Advances in Program for Development of Therapeutic Products for Cessation of Smokeless Tobacco Use and Addiction -- A Market Estimated to Exceed $2 Billion in the U.S.
LAS VEGAS, NV--On Thursday, November 10, 2016 at 5:00PM EST, Joseph Dowling, Chief Financial Officer at CV Sciences, Inc. discussed its drug development program and specifically its drug candidate utilizing synthetically-formulated CBD for use in treatment of smokeless tobacco addiction. According to Statista, there were approximately $5.3 billion in retail sales of smokeless tobacco products in 2014, and approximately 1.3 billion units of smokeless tobacco products sold during that time. Smokeless tobacco addiction is a huge unmet medical need, as there are currently no FDA-approved drugs to treat this widespread and deadly addiction. The current treatment market in the U.S. alone is estimated at greater than $2 billion.
The recording of the webcast discussing the Company's initial drug candidate (CVSI-007), which is a chewing gum that combines synthetic CBD and nicotine, is available at the link below:
ITS=TIME=TO=BUY=CVSI! ALL-MARIJUANA-STOCKS-GOING-GREEN-REAL-TIME!!! THIS IS MY LAST FREE POST FOR THE DAY!!! HAVE A GREAT WEEKEND FOLKS!!! ONWARD AND UPWARD!!! THE WORST IS NOW PAST US!
MJN@ Just Went GREEN After Being-Down-30%-This-Morning-SLAP-THAT-ASK-CVSI-ITS-TIME-TO-RUN-SUPER-THIN-ON-THE-ASK-TO-.60's!!!
MJN@ STILL PUSHING A MARKET CAP 10 X HIGHER THAN CVSI!!! WE SHOULD NOT BE PULLING BACK, JUST BECAUSE STOCKS LIKE MJN@ PULLBACK! THIS HAS GOT TO BE THE MOST RIDICULOUS THING I'VE SEEN!
Even CN@B is now trading up DOUBLE % and like 30% off its low with practically no sales and no cash!
WE HAVE A MARKET CAP OF AROUND $24,000,000 MILLION! INSANE! ONLY 2 X SALES. The Majority of the other companies in the sector, do not even have any sales and have Zero Cash. I really hope the people on this message board are educated enough to understand that this should not be trading at the current level that it is.
AGREE! THIS IS THE ABSOLUTE BOTTOM FOLKS! I HAVE 50+ MARIJUANA STOCKS ON MY WATCH LIST AND 1 X 1 ARE NOW GOING GREEN!!! WE WILL CLOSE UP TODAY IN MY OPINION, AND IT WILL RUN LIKE A 500 LB GORILLA ONCE IT DOES!
I ALSO CONFIRMED THAT THERE IS A VERY LARGE SHORT POSITION ON $CVSI, THE SHORTS ARE PART OF THE REASON THIS PULLED BACK TO WHERE IT ALL STARTED! WE ARE THE ONLY MARIJUANA STOCK WITH LEGIT SALES, A DECENT BALANCE SHEET, AND A KEY PATENT, THAT HAS NOT AT LEAST DOUBLED FROM WHEN THIS RAN BEGAN, AS OF TODAY! THE OTHER STOCKS ARE STILL TRADING AT 2X 3X 5X FROM THE POINT THEY BEGAN TO RUN!!!
WE ARE THE LAGGARD! TAKE ADVANTAGE OF THE DISCOUNTED PRICES, AS THEY WILL NOT LAST FOR LONG!
BE FEARFUL WHEN OTHERS ARE GREEDY, AND GREEDY WHEN OTHERS ARE FEARFUL!
Im NOW counting 13 MARIJUANA stocks that just went Green in the last 10 minutes.
The Reason the sector was down so big yesterday was 100% due to the fear of how Trump with a Christie and Giuliani team would view Marijuana legislation.
Peter Thiel Now Eliminates the political risk!
Buying hand over fist today!
BUY EARLY IN MY OPINION! HUGE NEWS RELEASED!!!!!!BOOOYAAA Peter Thiel to join the Trump transition team... People who sold yesterday are going to be extremely angry they did!
TRUMP IS BRINGING ON BILLIONAIRE CANNABIS INVESTOR AND GETTING RID OF THAT PIG CHRISTIE! He's doing this because he knows 60% of the US Supports Cannabis and needs someone who understands how to legalize it nationally and to help develop infrastructure to support Marijuana!
Billionaire venture capitalist Peter Thiel is said to be joining President-elect Donald Trump’s transition team — and possibly leading it.
Business columnist Dan Primack reported late Thursday on LinkedIn that Thiel had agreed to join Trump’s team.
http://www.marketwatch.com/story/could-peter-thiel-lead-trumps-transition-team-2016-11-10
Paypal founder Peter Thiel becomes marijuana's first big investor
Thiel’s Founders Fund is the first institutional investor to put money into the nascent cannabis industry, which is still illegal in half the US
https://www.theguardian.com/business/2015/jan/08/cannabis-investor-peter-theil-paypal-founder
Founders Fund joins $75 million investment in cannabis company
Founders Fund, the investment firm created by Peter Thiel, has joined a $75 million funding round for Privateer Holdings. Its subsidiary, Marley Natural, sells marijuana.
http://fortune.com/2015/01/08/founders-fund-privateer-holdings/
https://www.yahoo.com/news/silicon-valley-venture-capitalist-peter-014206689.html
Peter Thiel’s Founders Fund pours funds into the company behind Leafly, an online cannabis community
http://venturebeat.com/2015/01/08/peter-thiels-founders-fund-pours-funds-into-the-company-behind-leafly-an-online-cannabis-community/
Marijuana investor Privateer raises $40 million on eve of U.S. elections
Thursday, November 03, 2016 7:41 p.m. CDT
SAN FRANCISCO (Reuters) - Marijuana private equity investor Privateer Holdings has raised $40 million in convertible debt ahead of next week's elections, with pot legalization on the ballot in nine U.S. states.
Several investors rushed to place their funds, while others held back to wait for the election results.
Of the nine states that will vote on Tuesday on legalizing medical or recreational marijuana, California ranks as the most important.
The most populous U.S. state is considering allowing recreational adult use.
If the measure passes, it is expected to legitimize part of a multi-billion-dollar black market and open new opportunities for companies ranging from software to pot delivery.
Financial services firm Cowen and Co forecasts a $50 billion U.S. market in a decade, up from $6 billion in legal sales today.
U.S. law prohibits marijuana but federal agencies so far have limited their enforcement effort for companies which follow local laws in states that have legalized pot.
Seattle-based Privateer is one of several funds and investment companies targeting marijuana businesses. It said investors were divided on when to make their moves.
“Most of the potential lead investors wanted to wait until after next Tuesday to invest,” Chief Executive Brendan Kennedy said in an interview.
Others were ready to invest, but it was difficult to agree on how to value Privateer, with the outcome of the state votes unclear. The presidential race was a secondary issue, he added.
“This is a way to sort of take capital from investors without having to negotiate the price," he said. Privateer hopes to raise $100 million in the next round, including the notes.
The valuation of the company will be set when the round closes, and convertible note holders will get a 15 percent discount when they get equity in Privateer, he said.
The company plans to put more than half of the round in companies outside the United States, including Canada and potentially Australia, he said.
(Reporting by Peter Henderson; Editing by Leslie Adler)
http://kdal610.com/news/articles/2016/nov/04/marijuana-investor-privateer-raises-40-million-on-eve-of-us-elections/
NOV15-NOV18 $CVSI AKA $CANV SPECIAL PRESENTATION, at the BIG MJ Expo Next Week. (Gonna Get alot more investor awareness)
(There hasn't been a press release on this yet, I just happened to of found it!)
Marijuana Business Conference Expo
November 15, 2016: Pre-Conference Workshops
November 16-18, 2016: Main Conference & Expo
The Rio All-Suites Hotel & Casino | Las Vegas, NV
Call (401) 354-7555 x1
Email CustomerService@MJBizDaily.com
CV Sciences – PlusCBDoil – Booth #506
Tango Room, 2:00-3:00 pm
The Cannabis Disruption: Bringing Hemp Back
Hemp-derived cannabidiol, or CBD, has been receiving a lot of attention for its tremendous promise on human health. Discover exactly why we believe hemp-derived CBD is here to stay, and what measures this category leader is doing to ensure the safest and most trusted CBD products available via our PlusCBD Oil™ brand.
https://mjbizconference.com/vendor-presentations/
Nov 14 - Nov 16th CVSI is PRESENTING! MJ for MDs Marijuana for Medical Professionals Conference / DENVER COLORODO
https://marijuanaformedicalprofessionals.com/
Zero Dilution at the current time! The next note doesn't become convertible until End of November and only in small tranches of $275,000 per month which is only about 500,000 shares over the course of a month starting in December 2016! It's all in the filings. We traded over $4 Million in stock just this week alone, do you really think $275,000 worth of stock will impact us much if at all.
CV Sciences.(CVSI) (CANV)
The stock saw nearly 3 times its average 30-day volume on Monday fueled by excitement in the marijuana sector. Share prices rallied up more than 75%. In most of the recent press releases, the company has been focused on extinguishing the remainder of its convertible debt and as of early March, CANV management confirmed that 100% of the outstanding convertible promissory notes have been retired.
Following the acquisition of CanX and Canabine earlier this year, the company has taken a firm stance on efforts to develop synthetically-formulated CBD for use in drug development activities. In particular, they are looking to pursue approval of the FDA for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient. Board Chairman James A. McNulty has been an active contributor to biotechnology and health care related companies, including BioDelivery Sciences International, Inc. (BDSI), Hedgepath Pharmaceuticals, Inc. (HPPI), Accentia Biopharmaceuticals, Inc., and Biovest International, Inc. He is also a former shareholder of CanX, which brings this full circle.
CanX Archives - Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™ http://marijuanastocks.com/tag/canx/
EX-99.1 2 cvsciences_ex9901.htm LETTER TO SHAREHOLDERS
Exhibit 99.1
September 19, 2016
Dear Fellow Shareholders of CV Sciences,
In just a short period of time, we have achieved several tremendous milestones since our last shareholder letter, issued in December 2015. Shortly afterward, in January of this year, we announced the acquisition of CanX Inc., to pivot our strategic focus from leading the market of hemp-derived cannabidiol (“CBD”) oil products into an expansive pharmaceutical company focused on the development and commercialization of innovative medicines. Given our already established position as a market leader in CBD consumer products, the shift in our corporate strategy to include drug development was a critical move because it positioned CV Sciences as a life science company, addressed sizeable multi-billion dollar markets and expanded our potential to increase shareholder value.
In June 2016, we announced the approval by Financial Industry Regulatory Authority (“FINRA”) for a name change to CV Sciences and our trading symbol of our common stock to “CVSL” This has prompted our rebranding initiative to include value-enhancing actions that we feel will drive long-term shareholder value. As a result, it is even more important for you as shareholders to understand with full transparency our ongoing objective, our growth initiatives and why this is a great time to be involved with CV Sciences as we move forward in this exciting time ahead.
Pivot into Drug Development to Address a $5.3 Billion Market Opportunity
In our previous shareholder letter, we discussed the significant infrastructure investments made to facilitate our growth and the importance of expanding our exposure to broader audiences interested in the overall health and wellness sector. We remain laser focused on this initiative and consistent in our message. With our acquisition of CanX Inc., we evolved into a life science company now operating in two distinct yet complementary segments: specialty pharmaceutical and consumer products, together diversifying and expanding our growth and value proposition.
Through CanX, we also acquired a proprietary drug portfolio, including a lead drug candidate utilizing synthetically formulated CBD for use in treatment of smokeless tobacco addiction. Nicotine is the largest drug addiction problem worldwide and represents a significant opportunity to develop an effective treatment for this addiction. According to Statista, there was approximately $5.3 billion in retail sales of smokeless tobacco products in 2014, and approximately 1.3 billion units of smokeless tobacco products were sold during that time. Smokeless tobacco addiction is an unmet need that addresses a massive market opportunity, and we believe that our initial drug candidate to treat smokeless tobacco addiction will dramatically improve patient outcomes for millions.
1
Our initial drug candidate (CVSI-007) is a chewing gum that combines synthetic CBD and nicotine, which we believe has the potential to effectively treat smokeless tobacco and tobacco addiction. We have a patent pending on the technology and are pursuing the 505(b)(2) FDA drug-approval pathway to bring to market. Our CVSI-007 drug candidate meets the three well-established requirements for successfully treating nicotine addiction, which include the following:
1) CBD: Inhibits MAO (monoamine oxidase) and provides antidepressant effects to replace tobacco alkaloids
2) Nicotine: Addresses nicotine addiction and cravings
3) Chewing Gum: Provides oral stimulation
Given that there are no FDA-approved drugs to treat smokeless tobacco addiction and that the FDA has approved numerous nicotine replacement therapy drugs (NRTs), we believe that our drug candidate will be extremely well-received in the market. Also, the FDA has recent drug development experience with CBD, which we believe could accelerate the drug development process and approval.
Accelerated Progress in Drug Development
Thus far, our drug development program has achieved great success. We have been hitting our milestones in great strides and are excited to share our progress in the following areas:
Ø Design of initial drug candidate ü
Ø Filing of initial patent (provisional) ü
Ø Formulation and production of proprietary CGMP synthetic CBD ü
Ø In-vitro assay of CBD as an MAO inhibitor ü
Ø Finalization of internal drug development program ü
Ø Establishment of drug development team ü
Ø Selection of contract manufacturer for drug candidate -in progress
Ø Preclinical animal studies: safety -in progress
Ø Preparation for pre-IND meeting - ongoing
Ø Preparation for IND filing -ongoing
We have been progressing well with our preclinical efforts and will keep you updated on all the latest developments as we plan on commencing our human studies in 2017.
CBD Division Continues to Drive Revenues
Those of you following our story the past several years are familiar with our consumer products division, which delivers botanical-based CBD products in the natural products market. Plus CBD Oil™, our top-selling brand, has more than 30 SKUs, including capsules, sprays, oils and topicals, and is sold in over 700 retail stores. This is a significant increase from the 120 locations we had a year ago and is a testament to the value of our brand, which continues to provide a strong platform for growth and value creation. As we’ve reiterated in the past, the natural products market continues to skyrocket, and we have been very fortunate to be one of the early movers in the CBD space. In fact, NEXT, the industry’s leading source of forward-looking insights into what’s next in natural, estimates that U.S. consumer sales of natural , organic and healthy products are forecasted to expand 64% from $153 billion in 2013 to $252 billion by 2019. This is a compound average growth rate (CAGR) of 8.6%, which is more than four times the projected growth rate of mainstream consumer packaged goods.
According to Hemp Industries Association (HIA), total retail value of hemp products sold in the U.S. in 2015 is estimated at $573 million, with $65 million coming from CBD products.
Our products are distributed nationally in health food stores, in health care providers’ offices and online, and we will continue expanding existing and new sales channels through the education and marketing efforts in partnership with broker relationships and physician educators. In the coming weeks, we will be announcing other upcoming product line extensions and new launches that include a new vape brand, a point-of-sale specialty beverage and a body care line, which will further contribute to our growth strategy.
2
Looking Ahead
We believe that we are establishing a framework for future progress. This includes the potential of our drug development company and the growth trajectory from our consumer products division. We have several important upcoming milestones that will increase the value of CV Sciences if our expectations of results prove successful.
On the capital markets side, we will continue to work toward an uplisting of our shares so that we can generate increased visibility, better liquidity and lower cost of capital, as well as attract a broader range of institutional investors.
Given that our priority is to serve our investors, we will continue exploring options to unlock value for the Company, including how to effectively finance and operate both our pharmaceutical and consumer product divisions. We are considering all possibilities to maximize the value of our operating assets for the benefit of our shareholders. With these developments in place, and meaningful milestones right in front of us, we believe this is an extremely opportune time to invest in CV Sciences, as what we are building here has all the ingredients required for long-term success and value creation for our stock, including:
• A stellar management team and board of directors
• A $5.3 billion addressable market focused on an unmet medical need for cessation of smokeless tobacco
• A proprietary drug in development that is undergoing review by the FDA for fast-track approval
• Our already established leadership in the multi-billion dollar natural products market
• An intellectual property portfolio
• Over 50 SKUs -products in over 700 retail stores
• The No. 1 selling brand of CBD supplements to consumers
On behalf of our board of directors and management team, we thank you for your investment in our company and your continued support. Together we believe we can provide significant value accretion to our stockholders.
/s/ Michael Mona Jr.
Michael Mona Jr.
CEO, President & Founder
Forward-Looking Disclaimer
This shareholder letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are valid only as of today, and we disclaim any obligation to update this information. Actual results may differ significantly from management’s expectations.
2688 S. Rainbow Boulevard, Suite B, Las Vegas, NV 89146 p: 800-290-2157
website: www.cvsciences.com
3
https://www.sec.gov/Archives/edgar/data/1510964/000168316816000173/cvsciences_ex9901.htm
Conference Call News! What Is The Buzz Surrounding CV Sciences Inc (OTCMKTS:CVSI)?
https://www.journaltranscript.com/2016/11/what-is-the-buzz-surrounding-cv-sciences-inc-otcmktscvsi/